107 results about "Cytokine storm" patented technology

A tumor immune T cell detection kit and method are provided. The kit includes specific primers for detecting specific quantitative expression of immune-related target genes in human peripheral blood T cells through subjecting the target genes to PCR amplification based on SYBR-Green quantitative PCR amplification. The immune-related target genes include receptor and ligand related target genes, NK cell related target genes and key cytokine genes. Expression profiles of the immune system related target genes in the human peripheral blood T cells can be accurately and quantitatively detected by the kit and the method successfully so that targets can be provided for accurate immune treatment of tumor patients. In a treatment process, cytokine storm response to immune treatment of a patient can be detected timely, thus providing guidance for avoiding adverse reactions. States of the immune system in the treatment process and after treatment are assessed, thus providing supports for adjusting the amount of an antibody medicine used for treatment or the feedback number of modified T cells and even target adjustments. The kit and the method are comprehensive in detection, rapid, quantitative, accurate, high in sensitivity and low in cost.

The invention relates to application of IFN-lambda in preparation of a drug for treating a patient infected with a novel coronavirus. The level of the novel coronavirus in the infected patient can be effectively reduced, and the IFN-lambda shows more excellent performance in the aspects of controlling cytokine storm caused in the treatment process and relieving respiratory distress syndrome caused by the cytokine storm.

The invention belongs to the technical field of biology, and particularly relates to an in-vitro cytokine storm model and a construction method and application thereof. The construction system of the in-vitro cytokine storm model contains a TNF-alpha factor, an IL-1[beta] factor, an IL-6 factor and vascular endothelial cells. The in-vitro cytokine storm model is formed by the body. According to the in-vitro cytokine storm model construction method, vascular endothelial cells, TNF-alpha factors, IL-1[beta] factors and IL-6 factors are incubated together. The invention discloses application of an in-vitro cytokine storm model in screening of anti-cytokine release syndrome drugs. The invention relates to an application of an in-vitro cytokine storm model in preparing and screening anti-cytokine release syndrome drugs. The in-vitro cytokine storm model disclosed by the invention is obtained by jointly treating vascular endothelial cells through three factors, namely TNF-alpha, IL-1[beta] and IL-6, the in-vitro cytokine storm model with high cell apoptosis rate and obviously reduced cell activity can be prepared, and a better basis is provided for research on inflammatory response related to multiple factors.

The invention discloses an in-vitro amplification method and an application of glioma-derived tumor infiltration lymphocytes (TIL), and belongs to the technical field of cell culture. The method comprises the following steps: pre-culturing TIL cells; and culturing and amplifying the TIL cells. According to the method, under the condition that glioma infiltrating lymphocytes are not separated, theTIL cells are directly induced and cultured, then a large number of TIL cells are amplified, the operation procedure is simple, consumed time is short, the TIL cell amplification number and cell activity can be obviously improved, and the method has a good effect of killing glioma tumor cells. In the steps of TIL cell culture and amplification, a low-concentration cytokine composite nutrient medium is adopted, so that the requirements of TIL cell culture and amplification are met, and the potential risk of cytokine storm in the subsequent treatment process is reduced.

The invention relates to the technical field of medicines, in particular to an application of GS-9620. Experiments prove that the GS-9620 can effectively inhibit replication of EV71 viruses, reduce the death rate of infected mice, improve clinical symptoms of the infected mice and relieve pathological injuries of muscles. The GS-9620, by inhibiting NK cells and macrophages, can inhibit secretion of various cytokines and reduce injury of a body caused by cytokine storm; therefore, an effect of treating hand-foot-and-mouth disease or herpangina caused by the EV71 viruses can be achieved effectively and safely.

A method for administering human umbilical cord blood mesenchymal stem cell transfusion immunotherapy to a patient for treatment of coronavirus infection. The method includes harvesting umbilical cord mesenchymal stem cells, culturing the stem cells, collecting and purifying the cultured stem cells, placing the purified stem cells into a transfusion bag, and intravenously transfusing the stem cells from the transfusion bag into the patient having the infection.

The invention relates to applications of trametinib to preparation of a drug for treating pulmonary inflammatory diseases and promotion of Tfh cell differentiation. The chemical formula is C26H23FIN5O4. The applications include an application of trametinib to promotion for Tfh cell differentiation and an application of trametinib to preparation of the drug for treating the pulmonary inflammatory diseases. The trametinib has beneficial effects as follows: cytokine storm caused by activation of T cells and mononuclear macrophages can be better inhibited, and meanwhile, Tfh differentiation, B cell maturation mediation and antibody production are promoted; and as abroad-spectrum immune regulation drug, the trametinib has an effect of promoting antibody production in the aspects of other viralpneumonia, virus infection or seedling inoculation.

The invention discloses an exosome secreted by an lncRNA gene modified cell and application, and belongs to the field of cell biology. The exosome is secreted by an HEK-293T cell strain obtained through genetic engineering, the HEK-293T cell strain stably expresses lncENAF, and the nucleotide sequence of the lncENAF is as shown in SEQ ID NO: 1. The exosome can effectively inhibit generation of lipopolysaccharide-induced macrophage cytokines, is a potential cytokine inhibitor, and provides a new direction for cytokine storm and treatment of autoimmune diseases.

The invention belongs to the technical field of CAR-T living body CT imaging, and particularly discloses a preparation method and application of a gold nanocage. The preparation method of the gold nanocage comprises the following steps of preparing CF3COOAg mother liquor; preparing polyvinylpyrrolidone mother liquor; preparing hydrochloric acid mother liquor; preparing NaHS mother liquor, and taking the NaHS mother liquor, ethylene glycol hydrochloride mother liquor, vinylpyrrolidone mother liquor and CF3COOAg mother liquor for reacting; transferring a reaction product obtained in the previousstep into a centrifugal tube, adding an acetone solution for washing and purifying, adding water into the product for dispersing, centrifuging to remove supernate, and washing to obtain a silver nanocubic solution; and preparing the gold nanocage by adopting an electrochemical replacement method. The gold nanocage is applied to a CAR-T living CT imaging agent. The method has the following beneficial effects that a cytokine storm is not easily caused; and CAR-T can be transfected at a time through electroporation, the operation process is simple, and the CAR-T has the advantages of high contrast and high specificity through CT imaging.

The invention belongs to the field of biological medicines and discloses an alveolar macrophage-like multifunctional nanoparticle loaded with an aggregation-induced emission photothermal material anda preparation method and use of the alveolar macrophage-like multifunctional nanoparticle. The nanoparticle is obtained by taking an aggregation-induced emission photosensitive molecule 2TPE-2NDTA anda polylactic acid/glycollic acid copolymer as a co-carrier to form a core of a nano-drug and coating the 2TPE-2NDTA and the polylactic acid/glycollic acid copolymer with an alveolar macrophage membrane through a design and synthesis. The nanoparticle also has a characteristics of a photo-thermal agent and can be excited by near-infrared laser, and generated heat is used for photo-thermal killingof novel coronaviruses. Meanwhile, since the alveolar macrophage membrane on an outer layer of a nano-drug has related receptors on a surface, the nano-drug can adsorb SARS-CoV-2 and cytokines, so that a purpose of resisting a cytokine storm is achieved. The alveolar macrophage-like multifunctional nanoparticle can also solve a disadvantage and a deficiency of a poor curative effect in a traditional antiviral treatment scheme and becomes a new antiviral treatment strategy.

The invention discloses application of a stilbene glucoside compound in preparation of a medicine for preventing and/or treating coronavirus infection diseases. The medicine prepared from the stilbene glucoside compound shows an inhibition effect on the SARS-CoV 3CL protease activity and an effect of inhibiting combination of an SARS-CoV S protein and host cells ACE2. Meanwhile, the medicine also has the effects of preventing and/or relieving cytokine storm caused by coronavirus infection and preventing and/or relieving acute inflammatory injury of multiple organs caused by coronavirus infection.

The invention discloses a human-derived CD-19 chimeric antigen receptor T lymphocyte vector which is characterized by comprising a plasmid vector for coding single-chain variable region genes of CD19monoclonal antibodies, nucleosomal histone monoclonal antibodies and FNEDB monoclonal antibodies. The vector is a lentiviral vector. The invention further discloses application of the human-derived CD-19 chimeric antigen receptor T lymphocyte vector in preparation of CATR cells. The vector is used for transduction of T lymphocytes, natural killer cells and mononuclear cells, and is applied to treating tumors, preferably treating reoccurrence in malignant lymphoma drugs as well as neoplastic hematologic disorders and lymphomas which are refractory and unsuccessful in bone marrow transplantationmatching. The human-derived CD-19 chimeric antigen receptor T lymphocyte vector disclosed by the invention has the beneficial effects that the vector constructed in the invention can achieve the effects of enhancing the targeted CD19 antigen transgenic T lymphocyte specificity, overcoming the tumor microenvironment inhibited immune cellular function and controlling cytokine storm in clinic treatment.

The invention provides a T cell for expressing an immunosuppressive checkpoint receptor molecule and an application of the T cell. The immunosuppressive checkpoint receptor molecule is expressed on aT cell membrane in a chimeric manner and comprises an immunosuppressive checkpoint and an immune activation signal structural domain, wherein the immunosuppressive checkpoint is a signal peptide, an extracellular domain and a transmembrane domain of the immunosuppressive checkpoint receptor molecule; the immune activation signal structural domain comprises a combination of a CD28 intracellular segment, CD3 zeta and TLR2; and the CD28 is located at the N end of the CD3 zeta, and the TLR2 is located at the C end of the CD3 zeta. Compared with wild type T cells, the T cell disclosed by the invention has a remarkably enhanced anti-immunosuppression effect, has a stronger killing effect on tumor cells expressing immunosuppression checkpoint ligands, does not cause cytokine storm, is higher in safety, and has a wider application prospect in the field of tumor treatment.

The invention relates to identification of specific immune cell subtypes in new coronavirus infected peripheral blood and application of the specific immune cell subtypes, and provides immune cell populations and subpopulations which play an important role in occurrence and development of COVID-19 diseases. The first class can be used for T cell immunotherapy, DC cell immunotherapy and B cell immunotherapy of new coronal pneumonia and immunotherapy of old patients; the second class can be used for screening and designing a medicine for inhibiting cytokine storm and a medicine for inhibiting T cell reduction; the third class can be used for diagnosis of new coronal pneumonia.